NTLA Stock Recent News
NTLA LATEST HEADLINES
CAMBRIDGE, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced the acceptance of an oral presentation from the Phase 1 portion of the ongoing NTLA-2002 Phase 1/2 study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2024, taking place May 31 – June 3 in Valencia, Spain. NTLA-2002 is an investigational in vivo CRISPR-based gene editing therapy in development as a single-dose treatment for hereditary angioedema (HAE), a rare genetic condition that leads to potentially life-threatening swelling attacks. The presentation will include updated safety and efficacy results from the Phase 1 study across all three dose cohorts (25 mg, 50 mg and 75 mg).
Intellia Therapeutics (NTLA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
These biotech stocks have missed out on market gains so far, falling in the double digits over the past year. But they are innovators with potential growth catalysts right around the corner.
Cathie Wood added to her positions in these biotech stocks this week. The famous investor seeks out undervalued innovators to add to her funds and hold onto for the long term.
Gene editing could revolutionize how millions of patients are treated all over the world. That could create big opportunities for some of the most exciting gene-editing stocks.
Intellia (NTLA) doses the first patient in the phase III MAGNITUDE study on NTLA-2001 for treating transthyretin amyloidosis with cardiomyopathy.
Intellia Therapeutics has two candidates in or close to entering late-stage studies. The company's shares could rise significantly if it records positive trial results.
Intellia Therapeutics is expected to give updates on a pair of programs. The quality of its data will determine how much the market reacts.
Intellia Therapeutics, Inc. (NTLA) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, NTLA broke through the 50-day moving average, which suggests a short-term bullish trend.
Ark Invest bought shares of Roku, 10x Genomics, and Intellia Therapeutics on Monday. Roku has shed more than one-third of its value over the past two weeks after a series of unfortunate events.